126 related articles for article (PubMed ID: 11843915)
21. Molecular identification of mutations associated with anti-tuberculosis drug resistance among strains of Mycobacterium tuberculosis.
Abbadi SH; Sameaa GA; Morlock G; Cooksey RC
Int J Infect Dis; 2009 Nov; 13(6):673-8. PubMed ID: 19138546
[TBL] [Abstract][Full Text] [Related]
22. A novel fusidic acid resistance determinant, fusF, in Staphylococcus cohnii.
Chen HJ; Hung WC; Lin YT; Tsai JC; Chiu HC; Hsueh PR; Teng LJ
J Antimicrob Chemother; 2015 Feb; 70(2):416-9. PubMed ID: 25313205
[TBL] [Abstract][Full Text] [Related]
23. Comparison of
Zong Z; Jing W; Shi J; Wen S; Zhang T; Huo F; Shang Y; Liang Q; Huang H; Pang Y
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844043
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin.
Woodford N; Afzal-Shah M; Warner M; Livermore DM
J Antimicrob Chemother; 2008 Oct; 62(4):766-8. PubMed ID: 18567573
[TBL] [Abstract][Full Text] [Related]
25. Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008).
Castanheira M; Watters AA; Mendes RE; Farrell DJ; Jones RN
J Antimicrob Chemother; 2010 Jul; 65(7):1353-8. PubMed ID: 20430787
[TBL] [Abstract][Full Text] [Related]
26. [An investigation on multiple drug resistance of the rifampin resistant strains of Mycobacterium tuberculosis].
Kuang T; Jin G; Song P; Li W; Wang Z
Wei Sheng Wu Xue Bao; 1998 Apr; 38(2):152-4. PubMed ID: 12549378
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of PR-39, a proline-arginine-rich peptide, against susceptible and multi-drug-resistant Mycobacterium tuberculosis.
Linde CM; Hoffner SE; Refai E; Andersson M
J Antimicrob Chemother; 2001 May; 47(5):575-80. PubMed ID: 11328767
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of CEM-102 (fusidic acid) against prevalent clones and resistant phenotypes of Staphylococcus aureus.
Sahm DF; Deane J; Pillar CM; Fernandes P
Antimicrob Agents Chemother; 2013 Sep; 57(9):4535-6. PubMed ID: 23774441
[TBL] [Abstract][Full Text] [Related]
29. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis.
Richter E; Rüsch-Gerdes S; Hillemann D
Antimicrob Agents Chemother; 2007 Apr; 51(4):1534-6. PubMed ID: 17242139
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the susceptibility testing of clinical isolates of Mycobacterium tuberculosis by the XTT colorimetric method and the NCCLS standards method.
De Logu A; Pellerano ML; Sanna A; Pusceddu MC; Uda P; Saddi B
Int J Antimicrob Agents; 2003 Mar; 21(3):244-50. PubMed ID: 12636986
[TBL] [Abstract][Full Text] [Related]
31. Drug resistance among Mycobacterium tuberculosis strains in immigrants: is there a real threat everywhere?
Esteban J; Granizo JJ; Alvarez-Castillo MC; Soriano F
Clin Microbiol Infect; 2004 Apr; 10(4):335-6. PubMed ID: 15059124
[TBL] [Abstract][Full Text] [Related]
32. Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China.
Zhu C; Zhang Y; Shen Y; Siu GK; Wu W; Qian X; Deng G; Xu Y; Lau R; Fan X; Zhang W; Lu H; Yam WC
Diagn Microbiol Infect Dis; 2012 Jul; 73(3):260-3. PubMed ID: 22560167
[TBL] [Abstract][Full Text] [Related]
33. [In vitro sensitivity of methicillin-resistant Staphylococcus aureus to fusidic acid and trimethoprim-sulfamethoxazole].
Memikoğlu KO; Bayar B; Kurt O; Cokça F
Mikrobiyol Bul; 2002 Apr; 36(2):141-5. PubMed ID: 12652865
[TBL] [Abstract][Full Text] [Related]
34. Pyrazinamide resistance among drug-resistant Mycobacterium tuberculosis isolates at a referral hospital.
Arora J; Sidiq Z; Visalakshi P; Bhalla M; Behera D; Myneedu VP
Diagn Microbiol Infect Dis; 2013 Dec; 77(4):380-1. PubMed ID: 24075630
[No Abstract] [Full Text] [Related]
35. Characterization of mutations in streptomycin-resistant Mycobacterium tuberculosis clinical isolates in the area of Barcelona.
Tudó G; Rey E; Borrell S; Alcaide F; Codina G; Coll P; Martín-Casabona N; Montemayor M; Moure R; Orcau A; Salvadó M; Vicente E; González-Martín J
J Antimicrob Chemother; 2010 Nov; 65(11):2341-6. PubMed ID: 20802233
[TBL] [Abstract][Full Text] [Related]
36. Drug repurposing: Fusidic acid as a potential inhibitor of M. tuberculosis FtsZ polymerization - Insight from DFT calculations, molecular docking and molecular dynamics simulations.
Akinpelu OI; Lawal MM; Kumalo HM; Mhlongo NN
Tuberculosis (Edinb); 2020 Mar; 121():101920. PubMed ID: 32279872
[TBL] [Abstract][Full Text] [Related]
37. [Detection and Molecular Analysis of Moxifloxacin MIC Values of Mycobacterium tuberculosis Strains Isolated from Clinical Specimens].
Bozok T; Kayar B; Yakıcı G; Eker E; Marzi M; Karslı F; Köksal F
Mikrobiyol Bul; 2019 Jul; 53(3):245-253. PubMed ID: 31414626
[TBL] [Abstract][Full Text] [Related]
38. Drug resistance patterns of Mycobacterium tuberculosis in Riyadh, Saudi Arabia.
Kordy FN; Al-Thawadi S; Alrajhi AA
Int J Tuberc Lung Dis; 2004 Aug; 8(8):1007-11. PubMed ID: 15305485
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the microscopic observation drug susceptibility assay for detection of Mycobacterium tuberculosis resistance to pyrazinamide.
Ghiraldi LD; Campanerut PA; Spositto FL; Sato DN; Leite CQ; Hirata M; Hirata RD; Cardoso RF
Clin Microbiol Infect; 2011 Dec; 17(12):1792-7. PubMed ID: 21595790
[TBL] [Abstract][Full Text] [Related]
40. Molecular epidemiology study of Mycobacterium tuberculosis and its susceptibility to anti-tuberculosis drugs in Indonesia.
Lisdawati V; Puspandari N; Rif'ati L; Soekarno T; M M; K S; Ratnasari L; Izzatun N; Parwati I
BMC Infect Dis; 2015 Aug; 15():366. PubMed ID: 26297576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
